New cell therapy trial aims to tame eye inflammation
NCT ID NCT07427628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a one-time cell therapy called TRX103 for people with active non-infectious uveitis, a condition causing inflammation inside the eye. Up to 18 adults aged 18 to 70 will receive the treatment by IV and be monitored for a year. The main goal is to check safety and side effects, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-INFECTIOUS UVEITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Byers Eye Institute
Palo Alto, California, 94303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••